- Home
- RBNE vs NERV Comparison
RBNE vs NERV Comparison
Compare RBNE & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBNE | NERV |
|---|---|---|
| Founded | 2024 | 2007 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 269.6M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | RBNE | NERV |
|---|---|---|
| Price | $2.45 | $6.03 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 11.8M | 330.1K |
| Earning Date | 04-17-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.67 | $1.15 |
| 52 Week High | $20.57 | $12.46 |
Technical Indicators
Market Signals| Indicator | RBNE | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 43.14 |
| Support Level | $1.56 | $5.47 |
| Resistance Level | $3.81 | $6.69 |
| Average True Range (ATR) | 0.39 | 0.67 |
| MACD | 0.17 | -0.24 |
| Stochastic Oscillator | 71.88 | 11.40 |
Price Performance
Historical ComparisonAbout RBNE Robin Energy Ltd.
Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.